By IANS
Mumbai : Karnataka-based pharmaceuticals firm Shilpa Medicare Ltd said Friday that it would sell its cancer drug in Europe.
The European Directorate for the Quality of Medicines (EDQM) has given a green signal for the sale of Oxaliplatin EP, prescribed in the treatment of colon and rectal cancer, the company said here.
The EDQM has granted its certificate of suitability (COS) for the drug. The firm said it was the first in India and fifth in the world to get a COS from EDQM.
The drug used after chemotherapy or associated treatment of rectal and colon cancer has a worldwide sale of $1.9 billion in 2006 with a growth rate of 28 percent every year, the company said.
SUPPORT TWOCIRCLES
HELP SUPPORT INDEPENDENT AND NON-PROFIT MEDIA. DONATE HERE